Figure S7 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Key Points

• MAIN FINDING: Combination therapy using RAS(ON) inhibitors leads to long-term tumor control in pancreatic cancer.
• KEY EVIDENCE: The treatment prompted senescence-associated immune equilibrium, stabilizing tumor dynamics.
• APPROACH: The research utilized a differentiated mouse model of pancreatic ductal adenocarcinoma for the evaluations.
• SIGNIFICANCE: These findings suggest a potential strategy for improving therapeutic outcomes in pancreatic cancer patients.